Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients

Paik Seong Lim*, Chin San Liu, Chen Jee Hong, Yau Huei Wei

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

19 Scopus citations

Abstract

Background. Several studies have demonstrated that atherosclerotic complications are the major cause of morbidity and mortality in end-stage renal disease (ESRD) patients on dialysis. The allele ε4 of apolipoprotein E (ApoE) gene has been associated with an increased risk for ischaemic cerebrovascular disease (ICVD) in general populations in recent preliminary cross-sectional studies. Methods. The aim of our study was to prospectively investigate the risk of ischaemic cerebrovascular disease with respect to the presence of Apo ε4 allele in 157 Chinese uraemic patients. Results. During the 2 year follow-up, the incidence of stroke was 6.4% and the cumulative occurrence of ischaemic cerebrovascular disease was 9.6%. Further analysis showed that the cumulative occurrence of ischaemic cerebrovascular disease was 5.6% in subjects with no ApoE ε4 allele and 36.8% in those with one or two ApoE ε4 alleles. Univariate analysis showed that the prevalence of ischaemic cerebrovascular disease was significantly higher in the subjects with ApoE ε4 allele. The mean ApoA1 plasma concentrations was significantly lower in those with ApoE ε4 allele. A stepwise regression analysis showed that the presence of stroke was significantly related to the ApoE ε4 genotype (P < 0.001). Conclusions. The ApoE ε4 allele can be regarded as an important risk factor for ischaemic cerebrovascular disease in uraemic patients.

Original languageEnglish
Pages (from-to)1916-1920
Number of pages5
JournalNephrology Dialysis Transplantation
Volume12
Issue number9
DOIs
StatePublished - 09 1997
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients'. Together they form a unique fingerprint.

Cite this